Naxos Disease (Naxos Arrhythmogenic Cardiocutaneous Syndrome)
Are You Confident of the Diagnosis?
What to be alert for in the history
Naxos disease associates arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) with woolly hair and palmoplantar keratoderma (naxos arrhythmogenic cardiocutaneous syndrome). It is a genetically determined desmosomal defect, usually with an autosomal recessive inheritance; however, dominant forms have also been reported. Woolly hair is usually present from birth (
Typical appearance of woolly hair in a 7-year-old child with Naxos disease homozygous for JUP mutation
Keratoderma along the tendons on palmar and diffuse in plantar areas in a 6-year-old boy with Naxos disease
Usually there are no signs of heart disease up to the age of 12 years. At that point, initial findings include premature ventricular beats and minor depolarization abnormalities consisting of prolongation of terminal activation duration of the QRS complex on anterior precordial leads (V1-V3) more or equal than 55ms on a 12-lead standard electrocardiogram (ECG) and/or late potentials on signal-averaged ECG. Tiny waves at the end of QRS complex or at the beginning of ST segment are specific 12-lead ECG findings (
Twelve-lead resting ECG of a patient with Naxos disease diagnostic for ARVC/D repolarization and depolarization abnormalities.
Right ventricular structural/functional alterations (regional akinesia, dyskinesia or aneurysm and dilatation) detectable on 2-dimensional echocardiography, cardiac magnetic resonance (CMR) or angiography usually follow the ECG changes. Left ventricular involvement, being related to age and disease severity, ranges from regional hypokinesia mainly of posteroapical wall to global dilatation and diffuse hypokinesia.
Late enhancement imaging on CMR suggests early left ventricular involvement (fibrosis at subepicardial/mediomural layers).
Palpitations, presyncope or syncope are alarming signs of severe ventricular arrhythmia development (
Ventricular tachycardia of 250 beats per minute, in a patient with Naxos disease cardioverted by DC-shock.
Family history of similar cardiocutaneous phenotype and/or parental consanguinity should be sought.
Expected results of diagnostic studies
Skin histology reveals nonspecific features of keratoderma. Endomyocardial biopsy performed upon clinical indications reveals myocyte degeneration with strands of surviving myocytes surrounded by fibrous tissue embedded within adipocytes. Lymphocyte infiltrates might be observed, particularly when biopsy is performed at the time of clinical progression (“hot phase” of ARVC).
Since involvement of ventricular myocardium is regional and the pathologic process extends mainly from subepicardial to mediomural layers, the sensitivity of endomyocardial biopsy is rather low. It might be increased when sampling is guided by cardiac imaging or electroanatomic voltage mapping.
Right ventricular free-wall endomyocardial biopsy should be performed in highly experienced interventional cardiology laboratories, taking the appropriate precautions to prevent myocardial perforation; resistance in withdrawing the biopsy sample is an indication of thin fibrotic area, so another site should be selected. In patients with left ventricular involvement, myocardial loss with fibrous or fibrofatty replacement has been observed mainly at subepicardial layers of posteroapical wall.
Immunohistology of myocardium reveals reduced plakoglobin signal at intercalated disks, independently of the mutated protein or the site of endomyocardial biopsy. Genetic evaluation may reveal either recessive or dominant mutations in desmosomal proteins (
Causative mutation with respect to cutaneous and cardiac involvement. DSP,desmoplakin;Jup, junction plakoglobin; LV;left ventricle; PPK, palmoplantar keratoderma; RV, right ventricle
Causative mutation with respect to cutaneous and cardiac involvement. Alop, alopecia; DSP, desmoplakin; LV, left ventricle; PPK, palmoplantar keratoderma; RV, right ventricle
ARVC/D is diagnosed when 2 major diagnostic criteria, or 1 major plus 2 minor, or 4 minor criteria are fulfilled. (
Established criteria for ARVC/D diagnosis
Who is at Risk for Developing this Disease?
Most reports of Naxos disease come from countries of the East Mediterranean area. However, a few cases have been described in other places in the world.
The incidence of heterozygous carriers of plakoglobin mutation (2157del2) in the population of the Aegean islands has been estimated in up to 5%. Although heterozygous carriers do not develop the disease, being parents transmits a risk of homozygosity in 25% of every child. Few heterozygotes present with woolly hair with or without mild palmoplantar keratoderma and minor cardiac abnormalities not fulfilling the diagnostic criteria for ARVC/D.
The hair/skin phenotype in a child should alert for signs of cardiomyopathy. Annual follow-up with resting 12-lead ECG, signal-averaged ECG, 24-hour ambulatory ECG and 2-dimensional echocardiography targeted to detection of early signs consistent with ARVC/D should be applied after the 10th year of age.
What is the Cause of the Disease?
The first gene identified for Naxos disease and also for ARVC/D is a mutation in plakoglobin (JUP) resulting in frameshift and premature termination of translation. This homozygous 2-base-pair 2157 deletion of the protein gene results in Naxos cardiocutaneous phenotype.
In the protein product, the last 5 amino acid residues in the 13th armadillo repeat have been altered, with truncation of the C-terminal domain by 56 residues. Plakoglobin is a multifunctional adhesive and signaling protein of both adherens junctions and desmosomes (area composita). Consequently, recessive, dominant or compound heterozygous mutations in other desmosomal proteins (desmoplakin and desmocollin-2) have been identified to underly Naxos arrhythmogenic cardiocutaneous syndrome. Under the recent advances in characterization of ARVC/D as arrhythmogenic cardiomyopathy (by inclusion of left dominant disease), the term Naxos arrhythmogenic cardiocutaneous syndrome is considered more appropriate.
Plakoglobin is a linker and signaling molecule. At the outer dense plaque of desmosomes joined with plakophilin, another armadillo protein, plakogloblin interlinks desmosomal cadherins to desmoplakin. The whole complex is a securing anchorage of intermediate filaments of desmin (myocardium) or keratin (epidermis) to the cell membrane.
Plakoglobin is also essential in hair follicle proliferation and differentiation, a mechanism shown to be critically dependent on cell-cell attachment, its signaling role mainly expressed by competing with β-catenin in its Wnt signaling pathway. This is involved in regulation of cell growth, survival or death of epithelial tissues.
Therefore, plakoglobin apart from being a buckle in the cell-cell adhesive chain, shows a significant signaling role. Recent studies have indicated that plakoglobin is required for pemphigus antibodies to disrupt desmosomal adhesion. When plakoglobin is released from desmosomal plaque, due to a desmosomal protein defect, it might be translocated to the nucleus, possibly involved in transcriptional pathways.
The observation that palmoplantar keratoderma is a result of increased mechanical stress applied at these areas provides a working hypothesis for myocyte cell death in ARVC. On the other hand, keratoderma possibly reflects alterations in the keratinocyte differentiation program driven by desmosomal components. Involvement of a particular signalling mechanism might be fundamental in ARVC/D pathogenesis.
Immunohistology and electron microscopy of the heart in patients with Naxos disease confirm desmosomal dysfunction and support a relation to gap junction remodeling. This leads to an alternative pathway leading to intraventricular micro-reentry defects that might enhance the risk for ventricular arrhythmias (
Asimaki et al recently have shown that localization of plakoglobin at intercalated disks was reduced in all studied cases of ARVC/D underlied by a desmosomal mutation independently of the primarily affected protein. Thus, plakoglobin seems to play a key role to a final common pathway in ARVC/D pathogenesis.
Systemic Implications and Complications
- Recurrent ventricular arrhythmias
- Sudden death
Optimal Therapeutic Approach for this Disease
- All patients once diagnosed need to be promptly referred to a cardiologist. Follow-up with 12-lead resting ECG, signal averaged ECG, 24-hour ambulatory ECG, two-dimensional echocardiography yearly (in ages 10 to 20 years)
- Restriction of athletic activity
- Use of beta-blockers
- Antiarrhythmic drugs and catheter ablation to prevent ventricular tachycardia recurrences
- Implantable cardiac defibrillator (ICD) to prevent sudden death
- Combination of the above
- Medical treatment or heart transplantation for heart failure
- Palmar plantar keratoderma can be treated with lactic acid 5% to 12% cream or urea 10% to 20% cream on a daily basis if symptomatic. If asymptomatic, emollients are all that is required.
- No therapy for the woolly hair is needed.
Wooly hair does not need to be treated.
The keratoderma is difficult to treat. Bland emolients can be attempted. Keratolytic agents such as lactic acid 5% or 12% cream or urea 10% cream can be attempted. For pruritus, traimcinalone 0.025% to 0.1% can be used twice daily for 2 weeks at a time. Oral antihistamines are not useful.
The key to management is to have the patient follow up with a cardiologist who is fimiliar with the disease.
Unusual Clinical Scenarios to Consider in Patient Management
Although it is a rare disease mostly reported from East Mediterranean area, sporadic cases of Naxos syndrome have been reported from northern Europe, Spain and India. Sometimes associated with alopecia (early loss of hair) or dental anomalies. Mild cutaneous manifestations of Naxos syndrome should equally alert for cardiomyopathy signs and target to ARVC/D clinical/laboratory evaluation.
What is the Evidence?
Protonotarios, N, Tsatsopoulou, A, Patsourakos, P, Alexopoulos, D, Gezerlis, P, Simitsis, S. "Cardiac abnormalities in familial palmoplantar keratosis". Br Heart J. vol. 56. 1986. pp. 321-6.(First description of a recessive syndrome associating ARVC/D with woolly hair and palmoplantar keratoderma; familial ARVC/D; left ventricular involvement in ARVC/D.)
Kottke, MD, Delva, E, Kowalczyk, AP. "The desmosome: cell science lessons from human diseases". J Cell Sci. vol. 119. 2006. pp. 797-806.(Excellent review of the desmosome adhesion molecule.)(Article assessing the criteria for endomyocarial biopsy sampling to diagnose ARVC/D.)
Basso, C, Ronco, F, Marcus, F, Abudurheman, A, Rizzo, S, Frigo, AC. "Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria". Eur Heart J. vol. 29. 2008. pp. 2760-71.
Asimaki, A, Tandri, H, Huang, H, Halushka, MK, Gautam, S, Basso, C. "A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy". N Engl J Med. vol. 360. 2009. pp. 1075-84.(Eleven patients with arrythmogenic right ventricular cardiomyopathy were evaluated. Immunohistochemistry staining of plakoglobulin was nearly uniformly absent in heart biopsies from these patients, leading the authors to conclude this may be an important diagnostic test.)
Marcus, FI, McKenna, WJ, Sherrill, D, Basso, C, Bauce, B, Bluemke, DA. "Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia(ARVC/D): Proposed modification of the task force criteria". Circulation. vol. 121. 2010. pp. 1533-41.(Revision of diagnostic criteria for the diagnosis of ARVC/D.)
Delmar, M, McKenna, WJ. "The cardiac desmosome and arrhythmogenic cardiomyopathies: From gene to disease". Circ Res. vol. 107. 2010. pp. 700-714.(Comprehensive review on the role of desmosomal defects on ARVC/D pathogenesis and arrhythmogenesis; contribution of studies on Naxos disease. )
McKoy, G, Protonotarios, N, Crosby, A, Tsatsopoulou, A, Anastasakis, A, Coonar, A. "Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease)". Lancet. vol. 355. 2000. pp. 2119-24.(Study that showed Naxos disease was caused by a genetic mutation in the gene that encodes plakoglobin; first gene identified for ARVC/D, a mutation in desmosomal protein firstly reported as causing a cardiomyopathy.)
Protonotarios, N, Tsatsopoulou, A, Anastasakis, A, Sevdalis, E, McKoy, G, Stratos, K. "Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin". J Am Coll Cardiol. vol. 38. 2001. pp. 1477-84.(Review of cases with emphasis on characterizing features of the disease; risk stratification on ARVC/D.)
Protonotarios, N, Tsatsopoulou, A. "Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy". Cardiovasc Path. vol. 13. 2004. pp. 185-94.(Novel immunohistologic and ultrastructural findings on cell-cell junctions in ARVC/D myocardium in patients with Naxos disease.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Not All High-Risk Prostate Cancers Are the Same
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)